β-Lactams against Tuberculosis — New Trick for an Old Dog?

To the Editor: New treatments are needed to combat the worldwide increase in resistance to antituberculosis drugs. 1 The outlook for patients with tuberculosis who do not show a response to the key agents used in treatment — isoniazid, rifampin, fluoroquinolones, and aminoglycosides — is grim and re...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2016-07, Vol.375 (4), p.393-394
Hauptverfasser:	Diacon, Andreas H, van der Merwe, Lize, Barnard, Marinus, von Groote-Bidlingmaier, Florian, Lange, Christoph, García-Basteiro, Alberto L, Sevene, Esperança, Ballell, Lluís, Barros-Aguirre, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Amoxicillin-Potassium Clavulanate Combination - therapeutic use Antiretroviral agents Antitubercular Agents - therapeutic use beta-Lactamase Inhibitors - therapeutic use beta-Lactams - therapeutic use Cancer Chemotherapy Clinical trials Colony Count, Microbial Drug Discovery Drug resistance Fluoroquinolones Humans Isoniazid Mycobacterium tuberculosis Patients Rifampin Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!